Brief: AnaptysBio Q4 Net Income USD 49.614 Million
03/03/2026 21:15
Mar 03 (Reuters) - AnaptysBio Q4 collaboration revenue USD 108.249 million. Q4 operating expenses USD 41.348 million Q4 income from operations USD 66.901 million
Recent news on AnaptysBio
See all newsFirst Tracks Biotherapeutics up after $200 mln equity raise
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Brief: Anaptys Announces Second Quarter And Transitional Fiscal Year 2026 Financial Results And Provides Business Update
AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties